| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5154
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001194
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001193 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0784
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 |
| filingDate |
2001-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee48948431bf76df07042892e5f42d8b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e7cc437eece3207c52320d52191b9c9 |
| publicationDate |
2003-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2003175247-A1 |
| titleOfInvention |
Method to increase class I presentation of exogenous antigens by human dendritic cells |
| abstract |
Methods and compositions for use of human dendritic cells to activate T cells for immunotherapeutic responses against primary and metastatic cancer are disclosed. In one embodiment, human dendritic cells exposed to a tumor associated antigen, or an antigenic fragment thereof in combination with bacillus Calmette-Guerin (BCG), are administered to a cancer patient to activate a predominantly CD8 + T cell response in vivo. In an alternate embodiment, human dendritic cells are exposed to a tumor associated antigen or a specific antigenic peptide in combination with BCG in vitro and incubated or cultured with primed or unprimed T cells to activate a predominantly CD8 + T cell response in vitro. The activated T cells are then administered to a cancer patient. Antigen in combination with BCG is processed by dendritic cells through the MHC-CLASS I compartment which provides for a predominantly CD8 + T cell response. The addition of LPS provides for a greater number of mature dendritic cells enhancing the T cell response to antigen. Methods and compositions for human dendritic cells with extended life span and cryopreserved dendritic cells are disclosed. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011189093-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008254064-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005130899-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011084479-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8728465-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011104210-A1 |
| priorityDate |
2000-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |